Search Results
Your search for ,had matches 18497 pages
Showing 18201 - 18250Molecular Marker Predicts Patients Most Likely to Benefit Longest From EGFR Inhibitors
Scientists at Johns Hopkins have identified a molecular marker called Mig6 that appears to accurately predict longer survival—up to 2 years—among patients being treated with the EGFR inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Results from the preliminary study were published ...
Survival Advantage Seen in Glioblastoma Patients Taking Valganciclovir
Valganciclovir (Valcyte), a drug used to treat cytomegalovirus (CMV) eye infections in people with HIV/AIDS, may lengthen survival in patients with glioblastoma, a Swedish study has found. The researchers evaluated 50 patients with glioblastoma who received valganciclovir as an add-on to standard...
New Laser-Based Tool Could Dramatically Improve the Accuracy of Brain Tumor Surgery
A new laser-based technology may make brain tumor surgery much more accurate, allowing surgeons to tell cancer tissue from normal brain at the microscopic level while they are operating, and avoid leaving behind cells that could spawn a new tumor. In a new paper published in Science Translational...
Swallowing Exercises Preserve Function in Patients Receiving Radiation for Head and Neck Cancer
A study from UCLA's Jonsson Comprehensive Cancer Center (JCCC) has found that patients with head and neck cancer receiving radiation as part of their treatment were less likely to suffer unwanted side effects such as worsening of diet, need for a feeding tube, or narrowing of the throat passage if...
MRI Around the Time of Surgery Does Not Reduce Recurrence Rates in Women With DCIS
A large retrospective study reported that adding magnetic resonance imaging (MRI) to mammography before or immediately after surgery was not associated with reduced local recurrence or contralateral breast cancer rates among women with ductal carcinoma in situ (DCIS) of the breast who were treated...
Large Study Shows That Radiation Therapy for DCIS May Not Increase Cardiovascular Disease Risk
A large population-based study in the Netherlands found that women who had received radiation therapy to treat ductal carcinoma in situ of the breast (DCIS) have no increased risk of cardiovascular disease compared to the general population of Dutch women, nor compared to DCIS patients treated with ...
Most Women Have an Inaccurate Perception of Their Breast Cancer Risk, Study Reveals
A large-scale survey of women undergoing mammography screening on Long Island, New York, indicates that the majority (90.6%) either underestimate or overestimate their lifetime risk for developing breast cancer. Furthermore, 4 in 10 women surveyed reported they had never discussed their...
Quality of Life Improves Over Time and Is Similar in Long-Term Breast Cancer Survivors and Women With No History of Breast Cancer
In a study reported in Journal of Clinical Oncology, Pamela J. Goodwin, MD, and Tina Hsu of University of Toronto and colleagues assessed changes in quality of life from time of breast cancer diagnosis to long-term survivorship and compared quality of life in long-term survivors to that of...
New Ultrasensitive Screening Method Can Detect Colon Cancer in Its Early Stages
A new ultrasensitive screening method that detects genetic variations that initiate colon cancer and can help in the detection of the cancer in its early stages could be used for noninvasive colon cancer screening, according to a study by Bettina Scholtka, PhD, Assistant Professor in the Department ...
No Apparent Benefit of Adjuvant Gefitinib in Resected NSCLC in Prematurely Closed Trial
As reported in Journal of Clinical Oncology by Glenwood D. Goss, MD, of the Ottawa Hospital Cancer Center, and colleagues, the prematurely closed NCIC CTG BR19 study showed no apparent survival benefit of adjuvant gefitinib (Iressa) vs placebo in patients with completely resected non–small...
Germline Missense Mutations in BTNL2 Increase Susceptibility to Prostate Cancer
A team of researchers led by Janet Stanford, PhD, of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production—both of which impact immune function—increase the risk ...
No Survival Benefit of Adjuvant Ibandronate in High-Risk Early Breast Cancer
The effect of bisphosphonate treatment in early breast cancer is controversial, with some data indicating survival benefit in the adjuvant setting. In a study reported in Journal of Clinical Oncology, Gunter von Minckwitz, MD, of the German Breast Group in Neu-Isenberg and colleagues compared...
No Overall Survival Benefit With Brivanib in Advanced Hepatocellular Carcinoma Patients After Sorafenib Failure or Intolerance
The investigational agent brivanib is a selective dual inhibitor of VEGF and fibroblast growth factor receptors, both implicated in hepatocellular carcinoma. In a trial (BRISK-PS) reported in Journal of Clinical Oncology, Josep M. Llovet, MD, of the Icahn School of Medicine at Mount Sinai in New...
First-Line Brivanib Not Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma
The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...
Study Compares Rituximab Maintenance to Observation After First-Line Treatment in Older Patients With Advanced Follicular Lymphoma
In an Italian study reported in the Journal of Clinical Oncology by Umberto Vitolo, MD, and colleagues in the Fondazione Italiana Linfomi, treatment-naive patients aged > 60 years with advanced follicular lymphoma were randomized to rituximab [Rituxan] maintenance or observation after brief ...
Danish Study Evaluates Risk of Mental Disorders in Siblings of Childhood Cancer Survivors
Survivors of childhood cancer are at risk for long-term adverse physical and mental effects, but little is known about the effects of illness in siblings of these patients. In a study reported in Lancet Oncology, Lasse Wegener Lund, MD, of the Danish Cancer Society Research Centre in...
Vertebral Compression Fracture Risk Increased After Spinal Stereotactic Body Radiotherapy
In a study reported in the Journal of Clinical Oncology, Arjun Sahgal, MD, of Princess Margaret Cancer Centre in Toronto, and colleagues evaluated the occurrence of vertebral compression fractures in patients undergoing spinal stereotactic body radiotherapy. Vertebral compression fracture ...
In International Study, Patients Prefer Subcutaneous Over Intravenous Trastuzumab for Breast Cancer
Subcutaneous trastuzumab (not available in the United States) has been shown to have noninferior efficacy and similar pharmacokinetic and safety profiles compared with intravenous trastuzumab (Herceptin) in patients with early-stage HER2-positive breast cancer. In the PrefHer trial reported in...
Chinese Study Shows Icotinib Noninferior to Gefitinib in Advanced NSCLC
In the noninferiority ICOGEN trial reported in Lancet Oncology, Yuankai Shi, MD, of the Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs. Beijing, and colleagues compared the oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor icotinib with gefitinib...
NCI Study Links Hodgkin Lymphoma Treatment to Risk of Stomach Cancer
Hodgkin lymphoma survivors who received subdiaphragmatic radiotherapy and chemotherapy regimens containing high doses of the alkylating agent procarbazine (Matulane) were at an increased risk of developing stomach cancer, according to a large study by scientists at the National Cancer Institute...
Decreased White Matter Integrity and Neuropsychological Function Seen Decades After Cranial Radiotherapy for Pediatric Lymphoid Malignancies
CNS-directed chemotherapy and cranial radiation therapy for childhood acute lymphoblastic leukemia or lymphoma have neurotoxic effects. In a study reported in Journal of Clinical Oncology, Ilse Schuitema, MSc, of Leiden University, The Netherlands, and colleagues evaluated white matter changes ...
Genomic Differences Found in Two Types of Cervical Cancer
A study by Alexi Wright, MD, MPH, and colleagues at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston has found that two common subtypes of cervical cancer, adenocarcinoma and squamous cell carcinoma, have distinct molecular profiles. The results suggest that clinical...
Sorafenib Granted Priority Review for Differentiated Thyroid Cancer
Bayer HealthCare and Onyx Pharmaceuticals announced that the FDA has granted priority review designation to the supplemental new drug application of sorafenib (Nexavar) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. The...
Task Force Recommends Interventions to Prevent Tobacco Use in Children
The U.S. Preventive Services Task Force (USPSTF) today released its final recommendation statement on primary care interventions to prevent tobacco use in children and adolescents. The Task Force recommends that primary care clinicians provide interventions, including education or brief...
FDA Approves Mechlorethamine Gel for Cutaneous T-Cell Lymphoma
Ceptaris Therapeutics, Inc, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for the orphan drug mechlorethamine gel (Valchlor) for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who...
Single Injection of PV-10 Being Tested in the Treatment of Advanced Melanoma
A new study underway at Moffitt Cancer Center in Tampa, Florida, is investigating whether an intralesional injection of PV-10 (a substance derived from Rose Bengal, a staining agent that has been used to assess eye damage), is effective in reducing tumors and the spread of cancer in patients with...
Survival Advantage Seen in Foreign-Born Hispanics With NSCLC
Foreign-born Hispanics with non–small cell lung cancer (NSCLC) have a decreased risk of disease-specific mortality compared with non-Hispanic whites and United States-born Hispanics with NSCLC, according to a study published in the Journal of Clinical Oncology. Manali I. Patel, MD, and...
Meta-Analysis Indicates BEACOPPescalated Is Superior in Advanced Hodgkin Lymphoma
Studies evaluating two standards of care in adults with advanced Hodgkin lymphoma—ie, increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine (Matulane), and prednisone (BEACOPPescalated) and doxorubicin, bleomycin, vinblastine, and dacarbazine...
Panobinostat Combined With Bortezomib and Dexamethasone Can Recapture Responses in Heavily Pretreated Patients With Multiple Myeloma
The combination of the investigational histone deacetylase inhibitor panobinostat (Faridak) with bortezomib (Velcade) and dexamethasone was able to recapture responses in 34.5% of heavily pretreated, bortezomib-refractory patients with multiple myeloma in the phase II PANORAMA 2 trial. The 55...
Many Patients With Head and Neck Cancer Report Being Depressed, But Few Use Mental Health Services
Despite a relatively high rate of depression among patients with head and neck cancer following radiation therapy, mental health services were severely underutilized in this group, concluded researchers who analyzed questionnaire results from 211 patients. The patients had been previously treated...
Yoga Improves Sleep Quality in Cancer Patients With Sleep Disruption
It is estimated that 30% to 90% of cancer patients experience impairment of sleep quality post-treatment and such impairment can be severe enough to increase morbidity and mortality. Preliminary evidence indicates that yoga may improve sleep in cancer patients. In a study reported in the Journal of ...
Brain Cancer Survival Improved Following FDA Approval of Bevacizumab, Mayo Study Finds
A new population-based study has found that patients with glioblastoma who died in 2010, after the FDA approval of bevacizumab (Avastin), had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of brain...
Risk of Pancreatic Cancer May Be Reduced by Better Diet
In a study reported in the Journal of the National Cancer Institute, Hannah Arem, MHS, PhD, of the National Institutes of Health, and colleagues analyzed the association between quality of diet according to the 2005 Dietary Guidelines for Americans—Healthy Eating Index 2005...
NSABP B-38 Trial Shows No Benefit of Adding Fourth Drug to Standard Adjuvant Treatment in Women With Node-Positive Breast Cancer
Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. As reported in Journal of Clinical Oncology by Sandra M. Swain, MD, FACP, of Washington Cancer Institute–MedStar Washington Hospital Center, and colleagues,...
Night or Rotating Shift Work Associated With Increased Risk for High PSA
Some data support an association between circadian disruption and prostate cancer. In a study reported in Journal of the National Cancer Institute, Erin E. Flynn-Evans, PhD, of the Division of Sleep Medicine at Brigham and Women’s Hospital, and colleagues assessed the association between...
Study Determines Optimal Chemotherapy Regimen for Younger Patients With AML
In a study (Medical Research Council AML 15 Trial) reported in Journal of Clinical Oncology, Alan K. Burnett, MD, of Cardiff University School of Medicine and colleagues compared induction with daunorubicin/cytarabine, daunorubicin/cytarabine plus etoposide, and fludarabine/cytarabine/granulocyte...
New Research Suggests Restricting Calories May Improve Response to Cancer Treatment
New research suggests that restricting calories for a defined period of time may improve the success of cancer treatment, offering valuable new data on how caloric intake may play a role in programmed cancer cell death and efficacy of targeted cancer therapies. Study results were published online...
No Progression-Free Survival Difference for Cediranib or Cediranib/Lomustine vs Lomustine in Recurrent Glioblastoma
In a phase III study (REGAL trial) reported in Journal of Clinical Oncology, Tracy T. Batchelor, MD, MPH, of Massachusetts General Hospital, and colleagues compared oral monotherapy with the pan-VEGF tyrosine kinase inhibitor cediranib and the combination of cediranib plus lomustine (CeeNu) vs...
Poor Oral Health Is an Independent Risk Factor for Cancer-Causing Oral HPV Infection
Poor oral health, including gum disease and dental problems, is a newly recognized independent risk factor for oral human papillomavirus (HPV) infection, which causes between 40% and 80% of oropharyngeal cancers, according to a study published in Cancer Prevention Research. Researchers from the...
Similar 10-Year Survival in Patients With Early-Onset BRCA1-Negative and BRCA1-Positive Breast Cancer
In a study reported in Journal of Clinical Oncology, Tomasz Huzarski, MD, PhD, of Pomeranian Medical University, Szczecin, Poland, and colleagues from the Polish Hereditary Breast Cancer Consortium assessed survival among women with early-onset breast cancer with and without BRCA1 mutation and...
Multicenter Trial Finds BI-RADS 3 Breast Lesions Have Low Cancer Rate
Based on data from a multisite imaging trial involving more than 2,600 women, researchers say breast lesions categorized as “probably benign” on supplemental screening ultrasound could be reevaluated with imaging in 12 months, reducing patient anxiety, follow-up exams, and unnecessary...
New MRI Technique Reveals Brain Tumor Response to Antiangiogenesis Therapy
A new way of analyzing data acquired in magnetic resonance imaging (MRI) appears to be able to identify whether or not tumors are responding to antiangiogenesis therapy, which may help physicians determine the most appropriate treatments for patients. In a report published online in Nature...
Intrachromosomal Amplification of Chromosome 21 Associated With Poor Outcome in Children With ALL
Intrachromosomal amplification of a region of chromosome 21 (iAMP21; three or more extra copies of RUNX1 on an abnormal chromosome 21) is a recently identified recurrent genomic abnormality associated with poorer outcome in acute lymphoblastic leukemia (ALL). In a study reported in Journal of...
Neoadjuvant Carboplatin Before Radiotherapy May Reduce Risk of Relapse and Long-Term Side Effects in Men With Testicular Cancer
A new study published in the Annals of Oncology reports that giving men with testicular cancer a single dose of chemotherapy before radiotherapy could improve the effectiveness of treatment and reduce the risk of long-term side effects. As many as 96% of men with testicular cancer are predicted to ...
Finasteride Reduces Risk of Low-Grade Prostate Cancer With No Impact on Long-Term Survival
In the Prostate Cancer Prevention Trial (PCPT), initially reported in 2003, finasteride significantly reduced the risk of prostate cancer by 24.8% but was associated with a relative 26.9% increase in risk of high-grade disease compared with placebo. In a study reported in The New England Journal of ...
Best of ASCO 2013: Promises and Challenges of Applying Molecular Profiling to Clinical Practice
A “new kind of pathology,” in which anatomy and histology are supplemented by molecular etiology, has been emerging over the past decade and promises better response rates among cancer patients as genomic alterations in cancer continue to be identified and treated with targeted...
Study Finds 1 in 5 Women Don’t Believe Their Breast Cancer Risk
Despite taking a tailored risk assessment tool that factors in family history and personal habits, nearly 20% of women did not believe their breast cancer risk, according to a new study from the University of Michigan Comprehensive Cancer Center. The findings, published in Patient Education and...
Breastfeeding for More Than 6 Months May Protect Against Breast Cancer in Nonsmoking Women
A new analysis has found that breastfeeding for more than 6 months may safeguard nonsmoking mothers against breast cancer. However, the same does not seem to hold true for mothers who smoke. Published early online in the Journal of Clinical Nursing, the findings add to the list of benefits of...
‘Reprogrammed’ Treatment-Resistant Lymphomas Respond to Azacitidine
A phase I clinical trial showed diffuse large B-cell lymphomas resistant to chemotherapy can be reprogrammed to respond to treatment after being pretreated with drug azacitidine (Vidaza), according to a study published in Cancer Discovery. Patients whose lymphomas recur after initial chemotherapy...
Addition of Sunitinib to Capecitabine Does Not Improve Outcome in Previously Treated Metastatic Breast Cancer
A trial reported in Journal of Clinical Oncology by John P. Crown, MD, of the Irish Cooperative Oncology Research Group, and colleagues assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to capecitabine (Xeloda) in patients with previously treated metastatic breast cancer who...
